Depo-Provera--ethical issues in its testing and distribution.
Ethical issues relating to the use of the injectable contraceptive in developed and developing countries alike involve public policy decisions concerning both criteria for testing a new drug and individual choices about using a specific form of contraception approved for national distribution. Drug testing consists of an important but still evolving set of procedures. Depo-Provera is not qualitatively different from any other drug and some unpredictable risks are inevitable, even after extensive animal experiments and clinical trials. In assessing the risks and benefits of Depo-Provera use, epidemiological data from large-scale human use is now beginning to become more important than data from animal experiments and clinical trials. The consumer's best interest is central to any ethically responsible system of drug distribution. Systems of informed choice are needed, even in societies where illiteracy remains common and medical services are weak. In the case of a contraceptive, the risks of non-use leading to unintended pregnancy, which can result in high mortality, are relevant as well as the side-effects of the method. An attempt, therefore, is made here to categorise those issues which are universal and those which are country-specific.
D003271:Contraceptive Agents, Female / Q000633:toxicity*; D003906:Developing Countries; D030881:Disclosure; D004341:Drug Evaluation; D004992:Ethics, Medical; D005060:Europe; D005260:Female; D033161:Government Regulation; D006801:Humans; D007258:Informed Consent; D038622:Internationality; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000633:toxicity; D017258:Medroxyprogesterone Acetate; D018579:Patient Selection; D026684:Personal Autonomy; D011050:Policy Making; D035842:Research Subjects; D012306:Risk; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone